KURN Kuros Biosciences AG

Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

Kuros Biosciences AG / Key word(s): Miscellaneous
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

23.11.2022 / 07:00 CET/CEST


  • First investigational trial of drug-biologic bone graft for spinal fusion
  • No drug-related Serious Adverse Events (SAEs) reported in randomized stage of the trial
  • Enrollment of additional 20 patients for second non-randomized stage underway
  • Potential to address a major commercial opportunity

Schlieren (Zurich), Switzerland, 23 November, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the completion of enrollment in the randomized stage of the STRUCTURE trial, which is investigating the safety and efficacy of Fibrin-PTH (KUR-113) in transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease (DDD).

No drug-related SAEs were reported in the first stage of the Phase 2 randomized, dose-finding, multi-center study. The STRUCTURE trial is being conducted under an open Investigational New Drug (IND) program for spinal fusion, which was filed with the U.S. Food and Drug Administration (FDA) in 2020. STRUCTURE will enroll 50 patients with DDD requiring single-level interbody fusion with concomitant posterolateral fusion (PLF).

In the first stage of the trial, 30 patients were randomized into two arms, the first receiving Fibrin-PTH and the second receiving local autograft, which serves as control. Fibrin-PTH or local autograft were applied in and around FDA-cleared polyether-ether-ketone (PEEK) cages, respectively. Enrollment is underway for the remaining 20 patients for the second, non-randomized part of the trial, in which all subjects will receive Fibrin-PTH at a higher concentration. The primary endpoint of the trial is radiographic interbody fusion using CT scans at 12 months, as determined by an independent radiology expert panel.

Joost de Bruijn, Chief Executive Officer of Kuros, said: "We are very pleased with the progress we are making in this investigational trial, which is the first time a drug-biologic combination product candidate is being tested as a bone graft for the treatment of DDD in a controlled clinical setting. Fibrin-PTH has the potential to transform the way spinal fusions are performed and, as such, we see a substantial commercial opportunity around this product candidate. We are pressing ahead with the next stage of this trial and are looking forward to full enrollment of the study and primary endpoint read out of the randomized part of the study due next year."

For further information, please contact:

Kuros Biosciences AG 
Michael Grau
Chief Financial Officer
t: 7
e: 
LifeSci Advisors 
HansSandya von der Weid
Investors
t:
e: 

About Fibrin-PTH (KUR-113)
Fibrin-PTH (KUR-113) consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor (truncated human parathyroid hormone (PTH) analog. Fibrin-PTH (KUR-113) is designed to be applied directly into and around an intervertebral body fusion device as a gel, where it polymerizes in situ. Fibrin-PTH (KUR-113) functions via the well-established mechanism of action of parathyroid hormone; has been demonstrated in animal models of spinal fusion to be comparable to rhBMP-2; and has been shown in preclinical studies to be easy to use and ideal for open or minimally invasive techniques1*. The safety & efficacy of Fibrin-PTH (KUR-113) has not yet been evaluated for spinal fusion in humans. 

About Spinal Fusion
Lumbar fusion surgery is designed to create solid bone between adjoining vertebrae of the spine, eliminating any movement between the bones. Spinal fusion may be recommended for conditions such as spondylolisthesis, degenerative disc disease or recurrent disc herniations. The goal of fusion surgery is to reduce pain and nerve irritation. Surgeons perform lumbar fusion using several techniques. One such technique - Transforaminal Lumbar Interbody Fusion (TLIF) - is used to stabilize the spinal vertebrae. This definition is adapted from -health.com. It is estimated that the orthobiology market for spinal fusion is growing to $2.2 billion in 2030, while currently over 800,000 spinal fusion procedures are performed annually in the US & EU.

About Kuros Biosciences
Kuros Biosciences is a fast-growing leader in the development of spinal fusion biologics that ease the burden of back pain. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange.  The company’s first commercial product, MagnetOs, is a unique synthetic bone graft that has already been used successfully across three continents and in over 10,000 spinal fusion surgeries. The next candidate in the Kuros pipeline is Fibrin-PTH – the first drug-biologic combination for interbody spinal fusions, currently undergoing a Phase 2 clinical trial in the U.S. For more information on the company, its products and pipeline, visit .

Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

1. Data on file
*Results from in vivo laboratory testing may not be predictive of clinical experience in humans. 



End of Media Release


Language: English
Company: Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland
Phone:
Fax:
E-mail:
Internet:
ISIN: CH0325814116
Valor: 32581411
Listed: SIX Swiss Exchange
EQS News ID: 1494157

 
End of News EQS News Service

1494157  23.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1494157&application_name=news&site_id=research_pool
EN
23/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kuros Biosciences AG

Kuros Biosciences AG: 1 director

A director at Kuros Biosciences AG sold 225,000 shares at 20.900CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

 PRESS RELEASE

Kuros Biosciences Expands into Extremities Markets

Kuros Biosciences AG / Key word(s): Miscellaneous/Personnel Kuros Biosciences Expands into Extremities Markets 19.11.2024 / 07:00 CET/CEST Commercial Highlights Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company’s acceleration beyond the spine market  Strategic expansion opens new addressable market opportunity estimated at $1 billion Formation of a dedicated Surgeon Advisory Board to shape clinical and commercial strategies for MagnetOsTM in extremities markets Schlieren (Zurich), Switzerland, November 19, 2024 – Kuros Bioscie...

 PRESS RELEASE

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA...

Kuros Biosciences AG / Key word(s): Study results/Scientific publication Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft 25.06.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences, a leader in next generation bone healing technologies, today announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1 prospective, multi-center, randomized, intra-patient controlled clinical study in Spine1.   Published clinica...

 PRESS RELEASE

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences AG / Key word(s): AGMEGM Annual General Meeting of Kuros Biosciences approves all resolutions 17.04.2024 / 14:05 CET/CEST Schlieren (Zurich), Switzerland, April 17, 2024 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today.  The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2023 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and the Executive Committee, voted i...

 PRESS RELEASE

Kuros Biosciences to Report Full Year Financial Results for 2023 and P...

Kuros Biosciences AG / Key word(s): Annual Results Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update 08.03.2024 / 07:00 CET/CEST -    Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next-generation bone graft technologies, today announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024.  Following the announcement, the company w...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch